QIAGEN: Qiagen Full Year 2024 Earnings: EPS Misses Expectations

In This Article: Qiagen ( NYSE:QGEN ) Full Year 2024 Results Key Financial Results Revenue: US$1.98b (flat on FY 2023). Net income: US$83.6m (down 76% from FY 2023). Profit margin: 4.2% (down from 17% in FY 2023). EPS: US$0.39 (down from US$1.59 in FY 2023). We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. NYSE:QGEN Earnings and Revenue Growth April 2nd 2025 All figures shown in the chart above are for the trailing 12 month (TTM) period Qiagen EPS Misses Expectations Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 51%. Looking ahead, revenue is forecast to grow 6.8% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Life Sciences industry in the US. Performance of the American Life Sciences industry. The company's share price is broadly unchanged from a week ago. Risk Analysis We should say that we've discovered 2 warning signs for Qiagen that you should be aware of before investing here. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. NYSE:QGEN Earnings and Revenue Growth April 2nd 2025